Per a March 3, 2026 FDA press announcement (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies for making false or misleading claims about compounded GLP-1 products, including claims implying sameness with FDA-approved medications
The health effects of medical nutrition therapy by dietitians in patients with diabetes: a systematic review and meta-analysis: nutrition therapy and diabetes
You should not need to restart the titration from the beginning
Long-term data are needed to confirm the cardiovascular benefits of oral semaglutide
Deena Adimoolam, known by many of her patients as "Dr
It mimics GLP-1, a gut hormone the body releases after eating that reduces appetite, slows stomach emptying, and signals the brain that were full